![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TRIP10 |
Gene summary for TRIP10 |
![]() |
Gene information | Species | Human | Gene symbol | TRIP10 | Gene ID | 9322 |
Gene name | thyroid hormone receptor interactor 10 | |
Gene Alias | CIP4 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15642 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9322 | TRIP10 | ATC11 | Human | Thyroid | ATC | 3.03e-04 | 3.94e-01 | 0.3386 |
9322 | TRIP10 | ATC12 | Human | Thyroid | ATC | 3.91e-15 | 2.51e-01 | 0.34 |
9322 | TRIP10 | ATC13 | Human | Thyroid | ATC | 1.23e-23 | 3.39e-01 | 0.34 |
9322 | TRIP10 | ATC1 | Human | Thyroid | ATC | 3.57e-10 | 3.73e-01 | 0.2878 |
9322 | TRIP10 | ATC2 | Human | Thyroid | ATC | 2.41e-15 | 1.20e+00 | 0.34 |
9322 | TRIP10 | ATC3 | Human | Thyroid | ATC | 2.05e-06 | 5.06e-01 | 0.338 |
9322 | TRIP10 | ATC4 | Human | Thyroid | ATC | 3.50e-19 | 3.27e-01 | 0.34 |
9322 | TRIP10 | ATC5 | Human | Thyroid | ATC | 6.26e-21 | 3.83e-01 | 0.34 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049108 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIP10 | SNV | Missense_Mutation | novel | c.1735N>C | p.Thr579Pro | p.T579P | Q15642 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
TRIP10 | SNV | Missense_Mutation | rs201968771 | c.1603G>A | p.Glu535Lys | p.E535K | Q15642 | protein_coding | deleterious(0.04) | possibly_damaging(0.905) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TRIP10 | SNV | Missense_Mutation | novel | c.16N>C | p.Glu6Gln | p.E6Q | Q15642 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRIP10 | SNV | Missense_Mutation | c.1576N>G | p.Ile526Val | p.I526V | Q15642 | protein_coding | tolerated(0.37) | possibly_damaging(0.651) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
TRIP10 | SNV | Missense_Mutation | c.1628N>T | p.Gly543Val | p.G543V | Q15642 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
TRIP10 | deletion | Frame_Shift_Del | c.589delN | p.Phe197SerfsTer48 | p.F197Sfs*48 | Q15642 | protein_coding | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
TRIP10 | insertion | Frame_Shift_Ins | novel | c.1752dupA | p.Glu585ArgfsTer47 | p.E585Rfs*47 | Q15642 | protein_coding | TCGA-C8-A12Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
TRIP10 | deletion | Frame_Shift_Del | novel | c.1228delN | p.Arg410AlafsTer15 | p.R410Afs*15 | Q15642 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
TRIP10 | SNV | Missense_Mutation | c.424N>C | p.Glu142Gln | p.E142Q | Q15642 | protein_coding | deleterious(0) | benign(0.093) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
TRIP10 | SNV | Missense_Mutation | novel | c.1613N>T | p.Pro538Leu | p.P538L | Q15642 | protein_coding | tolerated(0.08) | benign(0.09) | TCGA-DS-A3LQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |